EBI3 Antibody (42N1G4) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-27356APC
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Western Blot
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Monoclonal Mouse IgG2b Kappa Clone # 42N1G4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full-length recombinant human EBI3 protein full length recombinant human EBI3 (cat # 100-162)
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2b Kappa
Applications for EBI3 Antibody (42N1G4) [Allophycocyanin]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: EBI3
Long Name
Epstein-Barr virus induced gene 3
Alternate Names
EBI-3, IL-27 beta, IL-27B, IL-35 EBI3, IL35 EBI3
Gene Symbol
EBI3
Additional EBI3 Products
Product Documents for EBI3 Antibody (42N1G4) [Allophycocyanin]
Product Specific Notices for EBI3 Antibody (42N1G4) [Allophycocyanin]
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...